article thumbnail

Daxxify, a New Anti-Wrinkle Drug and Botox Competitor is FDA-Approved

XTalks

Daxxify was FDA-approved for similar cosmetic purposes as Botox and other neuromodulators like Dysport and Xeomin. Many people choose to undergo non-invasive cosmetic procedures to prevent or reduce the appearance of signs of aging. A Novel Botox Competitor. ng of the core active ingredient. Bringing Daxxify into Offices.

Botox 98
article thumbnail

Skin Tone Explored: Unraveling Complexities Through Research!

Trialfacts

radiotherapy) in the past 6 months Must not have performed any aesthetic treatment on the face within the past 12 months, including injections (fillers/ Botox/ permanent implants, etc.), We are experts in the testing of haircare, cosmetics, and other personal care products. We help prove products are safe and effective.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ipsen’s John Chaddock on making neurotoxins a priority for healthcare systems

pharmaphorum

Though most people will know of these toxins through Allergan’s ‘Botox’ brand name and its association with cosmetic surgery, they can be used for a wide variety of medical indications and are often used to relieve spasticity in patients following stroke, traumatic brain injury or other neurological conditions. “The

Botox 105
article thumbnail

AbbVie Reports First-Quarter 2021 Financial Results

The Pharma Data

Global Botox Cosmetic net revenues were $477 million , an increase of 44.7 Global Botox Therapeutic net revenues were $532 million , an increase of 7.0 The updated Prescription Drug User Fee Act (PDUFA) action dates have been extended three months to late 2Q 2021 for PsA and early 3Q 2021 for AD. Recent Events.

Botox 40
article thumbnail

AbbVie Reports Second-Quarter 2021 Financial Results

The Pharma Data

Global Botox Therapeutic net revenues were $603 million, an increase of over 100.0 Global Botox Cosmetic net revenues were $584 million, an increase of over 100.0 AbbVie also presented real-world data on the role of Botox in combination with CGRP mAbs for Chronic Migraine prevention. percent on a reported basis, or 29.6

Botox 52
article thumbnail

Renuvion Dermal Handpiece by Apyx Medical Gets FDA Clearance for Wrinkle Reduction

XTalks

Common anti-aging procedures include Botox or dermal fillers, which can reduce the appearance of wrinkles, sagging and increase volume in the face where desired. Attendees will learn about the new US Food and Drug Administration (FDA) guidance and elements of a diversity plan.

article thumbnail

AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results

The Pharma Data

– Full-Year Global Net Revenues from the Aesthetics Portfolio Were $2.590 Billion; Global Botox Cosmetic Net Revenues Were $1.112 Billion. Global Botox Cosmetic net revenues were $493 million , an increase of 9.1 Global Botox Therapeutic net revenues were $567 million , a decrease of 1.0

Botox 52